TY  - JOUR
AU  - Minchom, Anna
AU  - Viteri, Santiago
AU  - Bazhenova, Lyudmila
AU  - Gadgeel, Shirish M
AU  - Ou, Sai-Hong Ignatius
AU  - Trigo, José
AU  - Bauml, Joshua M
AU  - Backenroth, Daniel
AU  - Bhattacharya, Archan
AU  - Li, Tracy
AU  - Mahadevia, Parthiv
AU  - Girard, Nicolas
PY  - 2022
DO  - 10.1016/j.lungcan.2022.03.005
UR  - http://hdl.handle.net/10668/22353
T2  - Lung cancer (Amsterdam, Netherlands)
AB  - In the single-arm CHRYSALIS study, amivantamab showed durable responses and manageable safety in patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins) who...
LA  - en
KW  - Amivantamab
KW  - Epidermal growth factor receptor
KW  - Exon 20 insertion
KW  - Non-small cell lung cancer
KW  - Real world
KW  - Antibodies, Bispecific
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Carcinoma, Non-Small-Cell Lung
KW  - ErbB Receptors
KW  - Exons
KW  - Humans
KW  - Lung Neoplasms
KW  - Mutagenesis, Insertional
KW  - Mutation
KW  - Platinum
KW  - Protein Kinase Inhibitors
TI  - Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy.
TY  - research article
VL  - 168
ER  -